Testimony to the FDA opposing midomafetamine (MDMA, “ecstasy”) as a treatment for PTSD
Public Citizen testified at a meeting of the FDA’s Psychopharmacologic Drug Advisory Committee regarding the psychedelic drug midomafetamine (MDMA, “ecstasy,” “molly”) as a potential treatment for posttraumatic stress disorder (PTSD). The drug is being considered for that indication in combination with intensive (8-hour) psychotherapy. In that testimony Public Citizen opposed approval of midomafetamine for PTSD because of concerns regarding both safety and effectiveness.